特应性皮炎患者静脉血栓栓塞风险:一项基于人群的队列研究
结果显示AD患者总体VTE风险与一般人群相似(aHR 1.04,95%CI 1.01-1.09),但重度AD患者风险升高(aHR 1.93,95%CI 1.70-2.14),尤其是18-39岁年轻成人(aHR 2.95,95%CI 2.40-3.59)。
要点
- AD患者总体VTE风险与一般人群相似,无需普遍筛查。
- 重度AD患者VTE风险约为一般人群的1.93倍,需警惕。
- 18-39岁重度AD患者VTE相对风险最高,达2.95倍。
核心结论
- AD患者总体VTE风险与一般人群相似,但重度AD患者风险升高,年轻成人尤为明显。
主要发现
- AD队列VTE发生率为1.49/1000人年,一般人群为1.71/1000人年。
- AD患者总体VTE风险与一般人群相似(aHR 1.04,95%CI 1.01-1.09)。
- 重度AD患者VTE风险高于一般人群(aHR 1.93,95%CI 1.70-2.14)。
- 18-39岁重度AD患者VTE风险为年龄匹配对照的2.95倍(aHR 2.95,95%CI 2.40-3.59)。
关键数值与推荐
- AD严重程度定义为使用系统性免疫调节治疗或因AD主要诊断住院。
- 重度AD定义为使用系统性免疫调节治疗或因AD主要诊断住院。
临床怎么用
- 多数AD患者无需因VTE风险进行额外筛查。
- 对重度AD患者,尤其是18-39岁年轻成人,应考虑密切监测VTE风险。
- 治疗决策时可结合VTE风险考虑预防措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is a common inflammatory skin disease. Evidence on baseline venous thromboembolism (VTE) risk is inconsistent, but a clear understanding of this risk may be crucial in disease management. OBJECTIVES: To evaluate whether individuals with AD have a higher risk of incident VTE than the general population and to assess variations in risk by demographics and disease severity. METHODS: This nationwide matched cohort study used Swedish health and population registers to examine VTE incidence in patients with AD. The study population included individuals diagnosed with AD who were aged ≥ 18 years from 1 January 2007. Patients with AD were matched by birth year and sex with up to five controls who did not have AD. AD severity was defined by use of systemic immunomodulatory treatment or hospitalization with AD as the primary diagnosis. Incidence rates per 1000 person-years were calculated for the AD cohort and the general population. Cox proportional hazard regressions were used to estimate VTE hazard ratios, adjusted for comorbidities, treatments and socioeconomic variables. Follow-up started at first AD diagnosis or 18th birthday and ended at first VTE event, emigration, death or end of study (31 December 2023). RESULTS: We identified 210 492 individuals with AD. These individuals were matched with 1 048 395 controls without AD. At inclusion, 94.1% had nonsevere AD and 5.9% had severe AD. The AD cohort had 3292 VTE events, with an incidence rate of 1.49 per 1000 person-years, compared with 1.71 per 1000 person-years in the general population. VTE risk was similar in individuals with AD and the general population [adjusted hazard ratio (aHR) 1.04, 95% confidence interval (CI) 1.01-1.09]. Those with severe AD had a higher VTE risk than the general population (aHR 1.93, 95% CI 1.70-2.14). Elevated VTE risk in severe AD was seen across all age groups. The youngest group (18-39 years) exhibited a higher relative risk than age-matched controls (aHR 2.95, 95% CI 2.40-3.59). CONCLUSIONS: This large population-based study found similar overall VTE risk between patients with AD and the general population, but higher risk in those with severe AD, particularly among younger adults. Further research is needed to clarify the clinical implications of these findings. Atopic dermatitis (AD), also known as eczema, is a common skin condition that causes inflammation, itching and discomfort. It affects millions of people worldwide, including up to 17% of adults in Europe. Some treatments for AD have been linked to an increased risk of blood clots. Such clots are also referred to as venous thromboembolism (VTE). VTE encompasses both deep vein thrombosis and pulmonary embolism. VTE can be serious or even life-threatening. This study, conducted in Sweden, aimed to find out whether people with AD are more likely to develop VTE compared with the general population. The researchers used national health records to follow over 210 000 adults with AD. For comparison, they also followed more than 1 million people without AD from 2007 to 2023. They found that, overall, people with AD did not have a higher risk of VTE than those without AD. However, people with severe AD (i.e. those needing injections, pills or hospital care) did have a higher risk. This was especially true for younger adults aged 18–39 years, who had nearly three times the risk of VTE compared with their peers without AD. These findings suggest that although most people with AD are not at increased risk of blood clots, those with severe forms of the disease may need closer monitoring. This is particularly true of young adults. This information can help doctors make safer treatment decisions. They may also consider preventive measures for those at higher risk of VTE.
引用
- Ivert LU, Anveden-Berglind I, Gembert K, et al. The risk of venous thromboembolism in atopic dermatitis: a population-based cohort study. Br J Dermatol. 2026. PMID: 41134699. doi:10.1093/bjd/ljaf418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。